Research programme: bispecific oncology antibodies - NovImmune

Drug Profile

Research programme: bispecific oncology antibodies - NovImmune

Alternative Names: NI 1601; NI 1701; NI 1801

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator NovImmune SA
  • Class Bispecific antibodies
  • Mechanism of Action CD19 antigen inhibitors; CD47 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Cancer; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 01 Apr 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association of Cancer Research (AACR-2016)
  • 03 Sep 2015 Novimmune and Baxalta agree to co-develop the bispecific antibody in Switzerland for an undefined indication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top